| Autor: |
Kivelevitch DN; Baylor University Medical Center, 3900 Junius Street, Suite 125, Dallas, TX 75246, USA., Menter A |
| Jazyk: |
angličtina |
| Zdroj: |
Immunotherapy [Immunotherapy] 2015; Vol. 7 (4), pp. 323-33. |
| DOI: |
10.2217/imt.14.113 |
| Abstrakt: |
Psoriasis is a chronic immune-mediated disease that affects 2-3% of the population worldwide. Over the past two decades new data on the physiopathology of psoriasis have opened the door for novel therapeutic options. The IL-23-Th17 axis has been shown to play a key role in the inflammatory cascade central to this disease. IL-17 inhibitors are a new group of drugs that have shown excellent clinical effectiveness for the treatment of moderate-to-severe psoriasis in current clinical trials. Brodalumab is an antibody against IL-17 receptor subunit A (IL-17RA). This article reviews the available published data on brodalumab for the treatment of moderate-to-severe psoriasis and psoriatic arthritis. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
